Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chia seeds (*Salvia hispanica* L.) are a nutrient-dense botanical product used as a functional food and dietary supplement for the management of metabolic and inflammatory conditions. Rich in alpha-linolenic acid (ALA), dietary fiber, and antioxidants, chia seeds—particularly the Salba strain—have been clinically evaluated for their efficacy in promoting weight loss and reducing visceral obesity in patients with type 2 diabetes. The mechanism of action involves the high fiber content, which enhances satiety and slows glucose absorption, alongside the anti-inflammatory properties of ALA, which lead to significant reductions in C-reactive protein (CRP) and pro-inflammatory cytokines like TNF-alpha. Clinical trials have also demonstrated their ability to modulate satiety-related hormones, including increasing adiponectin and decreasing ghrelin levels, thereby supporting long-term weight management and cardiovascular health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chia seeds.